Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor gene signature

Abstract

Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a OPRP genetic signature are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the genetic signature.

1 - 17 . (canceled) 
     
     
         18 . A method for genotyping a subject to determine the presence of a haplotype comprising the steps of:
 (a) obtaining a biological sample comprising genetic material of the subject, wherein the test subject is undergoing or is to undergo anti-psychotic pharmacotherapy;   (b) determining the presence of an Olanzapine Poor Response Predictor (OPRP) genetic signature in the biological sample, wherein the OPRP genetic signature is defined as a genotype comprising a homozygous genotype for the T allele at rs11960832 and either a homozygous or heterozygous genotype for the T allele at rs7975477.   
     
     
         19 . The method of  claim 18 , further comprising recording the determination of the genetic signature in a tangible medium. 
     
     
         20 . The method of  claim 19 , wherein the tangible medium comprises a computer-readable disk, a solid state memory device, or an optical storage device. 
     
     
         21 . The method of  claim 18 , further comprising extracting DNA from the biological sample. 
     
     
         22 . The method of  claim 18 , wherein the genetic material is analyzed by SNP genotyping or sequencing. 
     
     
         23 . The method of  claim 18 , further comprising reporting the determination to the subject, a health care payer, a physician, a pharmacist, a pharmacy benefits manager, or an electronic system. 
     
     
         24 . The method of  claim 18 , wherein the determining step is carried out through the use of an array or a kit comprising a plurality of primers or probes specific for the OPRP genetic signature, wherein the OPRP genetic signature is defined as a genotype comprising a homozygous genotype for the T allele at rs11960832 and either a homozygous or heterozygous genotype for the T allele at rs7975477. 
     
     
         25 . The method of  claim 18 , wherein the test subject is undergoing or is to undergo antipsychotic treatment with olanzapine, risperidone, quetiapine, ziprasidone, or perphenzazine.